Enhancement of the cellular immune response
US5798090A · kind A · utility
8Cited by
3References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 24, 1995 |
| Grant date | Aug 25, 1998 |
| Priority date | — |
| Expiry date | Feb 24, 2015 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K47/646
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
DTH-Effector cells are primed with carbohydrate antigens and used to enhance the cellular immune response. Tumors have been inhibited by DTH-Effector cells primed with epiglycanin and with synthetic T and Tn antigens. Either the DTH-Effector cells, or these tumor-associated carbohydrate antigens directly, may be used for tumor prophylaxis and therapy.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.